Join our daily newsletter At The Bell to receive exclusive market insights
- Imagion Biosystems (IBX) is set to present its prostate cancer research at the 2022 World Molecular Imaging Congress in Miami, Florida
- The research data relates to the company’s prostate cancer imaging agent, MagSense
- The data shows evidence the magnetic nanoparticle technology has the potential to target prostate cancer tumours which express the Prostate Specific Membrane Antigen with high specificity
- Further studies are still required to substantiate the imaging agent’s ability to detect clinically significant disease
- Imagion Biosystems last traded at 3.1 cents on September 27
Imagion Biosystems (IBX) is set to present its prostate cancer research at the 2022 World Molecular Imaging Congress in Miami, Florida.
The research data relates to Imagion’s prostate cancer imaging agent, MagSense. It shows strong evidence the magnetic nanoparticle technology has the potential to target prostate cancer tumours which express the Prostate Specific Membrane Antigen (PSMA) with high specificity.
The research shows the imaging agent is detectable by both MRI and Imagion’s proprietary magnetic relaxometry technology.
The company explained PSMA-targeting molecules were recently approved for use with PET tracers for the detection of prostate cancer metastases.
Imagion said its MagSense imaging agent leverages the same molecular target, but avoids the use of radioactive tracers. This offers a safer alternative for the non-invasive detection of prostate cancer.
Imagion Biosystems CEO Bob Proulx said the data is very encouraging.
“Knowing we have imaging agent that can work with multiple forms of magnetic imaging and does not use radioactivity will address the large unmet need of making non-invasive detection of prostate cancer more accessible and affordable and could reduce the need for prostate biopsies for many men, saving costs and improving patient care,” he said.
Further studies are still required to substantiate the imaging agent’s ability to detect clinically significant disease.
Imagion Biosystems last traded at 3.1 cents on September 27.
